

Günter Fasching, M.D.  
Liechtensteinstrasse 22  
A - 9073 Klagenfurt, AUSTRIA

Tel: +43-664-2001788, e-mail: [kinderchirurg@aon.at](mailto:kinderchirurg@aon.at)

---

---

Klagenfurt, february 14, 2008

European Commission  
Health and Consumer Protection Directorate-General  
Rare diseases consultation  
HTC 01/198  
11, Rue Eugène Ruppert  
L-2557 Luxembourg

**Re. Public Consultation regarding a European Action in the Field of Rare Diseases**

Dear Sir,

Thank you for the invitation to comment the planned activities of the EU as to rare diseases. As a paediatric surgeon I am concerned with congenital malformations and rare surgical diseases of neonates and infants.

Q1: acceptable, although there is quite a difference of the incidence in the various countries for one and the same disease

Q2: There is a pressing need to improve coding and classification

Q3: Yes; Austria is a small country, therefore the number of treated cases in different places is rather low.

Q4: The transfer of knowledge should be improved by defining of centres of excellence which can be contacted at any time; links to research groups; for the patients contact with other affected patients

Q5: defining of experienced reference laboratories for histological, immunochemical or genetic tests is a must

Q6: no personal experience

Q7: describing best practice is very important, exchange of knowledge and information

Q8: will address mostly metabolic disorders, in my country all medicaments are available

Q9: The mentioned specialised social services such as respite care services, help lines, therapeutic recreation programmes and financial and psychological support are very important

Q10: a really important issue

Q11: Research activities should be coordinated with a centrally surveillance, thus avoiding similar studies at different places; the money for research could be spent for really unique original studies. This affects also the funding policy, funding agencies should be in close cooperation.

Q12: I agree with 4.4 and 4.5

Q13: I feel that action plans are important, it could be on a regional or national level, respectively, depending on the kind of disease.

Q14: All activities could be centrally organised by a European Agency, so I think a feasibility study should be done.

I hope my short comments are sufficient, if not, please feel free to contact me.

With best regards,

Sincerely Yours

Günter Fasching, M.D.

Prof. of Paediatric Surgery, General Hospital Klagenfurt, Austria

e-mail: [g.fasching@lkh-klu.at](mailto:g.fasching@lkh-klu.at)

This paper represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.